Onkologie. 2023:17(4):252-255 | DOI: 10.36290/xon.2023.048

Role of ruxolitinib in treatment of polycythemia vera

Natália Podstavková
Interní hematologická a onkologická klinika, LF MU a FN, Brno

Ruxolitinib, selective oral inhibitor of Janus kinases JAK1/JAK2, is approved for therapy of primary myelofibrosis but also as a second line therapy of patients with polycythemia vera which are resistant or intolerant to hydroxyurea. Randomized studies RESPONSE and RESPONSE-2 have shown its superiority in achieving hematological remission and decreased symptom burden when compared to best available therapy. MAJIC-PV study demonstrated in PV benefits of ruxolitinib in superior event-free survival and prolonged overall survival of patients.

Keywords: Ph negative myeloproliferative neoplasms, polycythemia vera, ruxolitinib.

Accepted: October 3, 2023; Published: October 5, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Podstavková N. Role of ruxolitinib in treatment of polycythemia vera. Onkologie. 2023;17(4):252-255. doi: 10.36290/xon.2023.048.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92:289-297. Go to original source... Go to PubMed...
    2. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755-761. Go to original source... Go to PubMed...
    3. Tibes R, Mesa RA. Emerging drugs for polycythemia vera. Expert Opin Emerg Drugs. 2013;18:393-404. Go to original source... Go to PubMed...
    4. Spivak JL. Polycythemia Vera. Curr Treat Options Oncol. 2018;19(2):12. Go to original source... Go to PubMed...
    5. Hasselbalch HC, Holmstrom MO. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol. 2019;41:5-19. Go to original source... Go to PubMed...
    6. Spivak JL. Polycythemia Vera. Curr Treat Options Oncol. 2018;19(2):12. Go to original source... Go to PubMed...
    7. Abelsson J, Andreasson B, Samuelsson J, et al. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leuk Lymphoma. 2013;54:2226-2230. Go to original source... Go to PubMed...
    8. Griesshammer M, Gisslinger H, Mesa R. Current and future treatment options for polycythemia vera. Ann Hematol. 2015;94:901-910. Go to original source... Go to PubMed...
    9. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European Leu­kemiaNet. Leukemia. 2018;32(5):1057-1069. Go to original source... Go to PubMed...
    10. Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8(3):e175-e184. Go to original source... Go to PubMed...
    11. Scherber R, Dueck A, Kiladjian J, et al. Conventional therapeutic options have limited impact on MPN symptoms: Insights from a prospective analysis of the MPN-SAF TSS. Haematologica. 2012.
    12. Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119(6):1363-1369. Go to original source... Go to PubMed...
    13. Antonioli E, Guglielmelli P, Pieri L, et al. AGIMM Investigators. Hydroxyurea-related toxicity in 3,411 patients with Ph'-ne­gative MPN. Am J Hematol. 2012;87(5):552-554. Go to original source... Go to PubMed...
    14. Björkholm M, Hultcrantz M, Derolf ÅR. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated? Best Pract Res Clin Haematol. 2014;27(2):141-153. Go to original source... Go to PubMed...
    15. Marchetti M, Vannucchi AM, Griesshammer M, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9(4):301-311. Go to original source... Go to PubMed...
    16. Foltz L, Pica GM, Zerazhi H, et al. Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available. Leuk Lymphoma. 2019;60(14):3493-3502. Go to original source... Go to PubMed...
    17. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435. Go to original source... Go to PubMed...
    18. Harrison CN, Nangalia J, Boucher R, et al. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. J Clin Oncol. 2023;41(19):3534-3544. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.